Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Favipiravir: the hidden threat of mutagenic action

Zhirnov et al., Journal of microbiology, epidemiology and immunobiology, doi:10.36233/0372-9311-114
May 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Review of the mutagenic effect of favipiravir and associated concerns.
Reviews covering favipiravir for COVID-19 include Bacigalupo, Hadj Hassine, Waters, Zhirnov.
Zhirnov et al., 5 May 2021, Russia, peer-reviewed, 2 authors.
This PaperFavipiravirAll
Favipiravir: the hidden threat of mutagenic action
Oleg P Zhirnov, Alyona I Chernyshova
Journal of microbiology, epidemiology and immunobiology, doi:10.36233/0372-9311-114
The antiviral drug favipiravir (FPV), which is a structural analogue of guanosine, undergoes chemical transformation in infected cells by cellular enzymes into a nucleotide form -favipiravir ribose triphosphate (FPV-RTP). FPV-RTP is able to bind to viral RNA-dependent RNA polymerase and integrate into the viral RNA chain, causing a significant mutagenic effect through G→A and G→U transitions in the viral RNA genome. Besides the virus inhibiting effect, the increased synthesis of mutant virions under the action of FP possess a threat of the emergence of novel threatening viral strains with high pathogenicity for humans and animals and acquired resistance to chemotherapeutic compound. There are three ways to minimize this mutagenic effect of FP. (1) Synthesis of new FPV modifications lacking the ability to integrate into the synthesized viral RNA molecule. (2) The combined use of FPV with antiviral chemotherapeutic drugs of a different mechanism of action directed at various viral and/or host cell targets. (3) Permanent application of high therapeutic doses of FPV under the strict medical control to enhance the lethal mutagenic effect on an infectious virus in the recipient organism to prevent the multiplication of its mutant forms.
Author contribution. Аll authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published.
Abdelnabi, Morais, Leyssen, Imbert, Beaucourt et al., Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase, J. Virol, doi:10.1128/jvi.00487-17
Alyona, Chernyshova -Junior, Researcher, None
Arias, Thorne, Goodfellow, Favipiravir elicit antiviral mutagenesis during virus replication in vivo, eLife, doi:10.7554/elife.03679
Baranovich, Wong, Armstrong, Marjuki, Webby et al., T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, J. Virol, doi:10.1128/jvi.02346-12
Baz, Carbonneau, Rhéaume, Cavanagh, Boivin, Combination therapy with Oseltamivir and Favipiravir delays mortality but does not prevent Oseltamivir resistance in immunodeficient mice infected with pandemic A(H1N1) influenza virus, Viruses, doi:10.3390/v10110610
Beigel, Bao, Beeler, Manosuthi, Slandzicki et al., A randomized double-blind phase 2 study of combination antivirals for the treatment of influenza, Lancet, doi:10.1016/S1473-3099(17)30476-0
Bixler, Bocan, Wells, Wetzel, Van Tongeren et al., Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus, Antiviral Res, doi:10.1016/j.antiviral.2017.12.020
Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with Favipiravir for COVID-19: An open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007
De Ávila, Gallego, Soria, Gregori, Quer et al., Lethal mutagenesis of hepatitis C virus induced by Favipiravir, PLoS One, doi:10.1371/journal.pone.0164691
Delang, Abdelnabi, Neyts, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, Antiviral Res, doi:10.1016/j.anti-viral.2018.03.003
Du, Chen, Response to "Dose rationale for Favipiravir use in patients infected with SARS-CoV-2, Clin. Pharmacol. Ther, doi:10.1002/cpt.1878
Dunning, Baillie, Cao, Hayden, Antiviral combinations for severe influenza, Lancet Infect. Dis, doi:10.1016/S1473-3099
Eloy, Solas, Touret, Mentré, Malvy et al., Dose rationale for Favipiravir use in patients infected with SARS-CoV-2, Clin. Pharmacol. Ther, doi:10.1002/cpt.1877
Ferron, Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA, Proc. Natl. Acad. Sci, doi:10.1073/pnas.1718806115
Furuta, Egawa, Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both, European Patent Office WO
Furuta, Gowen, Takahashi, Shiraki, Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res, doi:10.1016/j.antiviral.2013.09.015
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc. Jpn Acad. Ser. B Phys. Biol. Sci, doi:10.2183/pjab.93.027
Furuta, Takahashi, Kuno-Maekawa, Sangawa, Uehara et al., Mechanism of action of T-705 against influenza virus, Antimicrob. Agents Chemother, doi:10.1128/AAC.49.3.981-986.2005
Goldhill, Velthuis, Fletcher, Langat, Zambon et al., The mechanism of resistance to Favipiravir in influenza, Proc. Natl Acad. Sci, doi:10.1073/pnas.1811345115
Grande-Pérez, Lazaro, Lowenstein, Domingo, Manrubia, Suppression of viral infectivity through lethal defection, Proc. Natl Acad. Sci, doi:10.1073/pnas.0408871102
Guedj, Piorkowski, Jacquot, Madelain, Nguyen et al., Antiviral efficacy of Favipiravir against Ebo la virus: A translational study in cynomolgus macaques, PLoS Med, doi:10.1371/journal.pmed.1002535
Hurt, Ison, Hayden, Hay, Second isirv antiviral group conference: overview. Influenza Other, Respir. Viru ses, doi:10.1111/irv.12207
Ilyushina, Bovin, Webster, Govorkova, Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants, Antiviral Res, doi:10.1016/j.antiviral.2006.01.012
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a phase II/III multicenter randomized clinical trial, Clin. Infect. Dis, doi:10.1093/cid/ciaa1176
Jordan, Stevens, Deval, Nucleosides for the treatment of respiratory RNA virus infections, Antivir. Chem. Chemother, doi:10.1177/2040206618764483
Joshi, Parkar, Ansari, Vora, Talwar et al., Role of Favipiravir in the treatment of COVID-19, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.10.069
Li, De Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat. Rev. Drug Discov, doi:10.1038/d41573-020-00016-0
Li, Yang, Liu, Yang, Zhao et al., Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019, Pharmacol. Res, doi:10.1016/j.phrs.2020.105036
Lu, Hardes, Dahms, Böttcher-Friebertshäuser, Steinmetzer et al., Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells, Antiviral Res, doi:10.1016/j.antiviral.2015.05.006
Naesens, Guddat, Keough, Van Kuilenburg, Meijer et al., Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir), Mol. Pharmacol, doi:10.1124/mol.113.087247
Neogi, Hill, Ambikan, Heng, Quinn et al., Feasibility of known RNA polymerase inhibitors as anti-SARS-CoV-2 drugs, Pathogens, doi:10.3390/pathogens9050320
Ortega, Zambrano, Jastrzebska, Liprandi, Rangel et al., Understanding severe acute respiratory syndrome coronavirus 2 replication to design efficient drug combination therapies, Intervirology, doi:10.1159/000512141
Perales, Gallego, De Ávila, Soria, Gregori et al., The increasing impact of lethal mutagenesis of viruses, Future Med. Chem, doi:10.4155/fmc-2018-0457
Perales, Mateo, Mateu, Domingo, Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants, J. Mol. Biol, doi:10.1016/j.jmb.2007.03.074
Pilkington, Pepperrell, Hill, A review of the safety of favipiravir -a potential treatment in the COVID-19 pandemic?, J. Virus Erad, doi:10.1016/s2055-6640(20)30016-9
Sada, Saraya, Ishii, Okayama, Hayashi et al., Detailed molecular interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus polymerases in silico, Microorganisms, doi:10.3390/microorganisms8101610
Sangawa, Komeno, Nishikawa, Yoshida, Takahashi et al., Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase, Antimicrob. Agents Chemother, doi:10.1128/aac.00649-13
Shannon, Selisko, Le, Huchting, Touret et al., Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in ЖУРНАЛ МИКРОБИОЛОГИИ
Shiraki, Daikoku, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, Pharmacol Ther, doi:10.1016/j.pharmthera.2020.107512
Smee, Hurst, Egawa, Takahashi, Kadota et al., Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J. Antimicrob, Chemother, doi:10.1093/jac/dkp274
Smith, Rajwanshi, Kim, Deval, The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase, PLoS One, doi:10.1371/journal.pone.0068347
Tsai, Lu, Bau, Chiu, Yen et al., Approaches towards fighting the COVID-19 pandemic (Review), Int. J. Mol. Med, doi:10.3892/ijmm.2020.4794
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell. Res, doi:10.1038/s41422-020-0282-0
Zhirnov -D. Sci ; Prof, Corr, Information about the authors Oleg
Zhirnov, High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination, J. Med. Virol, doi:10.1002/jmv.1890210208
Zhirnov, Molecular targets in the chemotherapy of coronavirus infection, Biochemistry (Mosc), doi:10.1134/S0006297920050016
Авторов, Все авторы внесли существенный вклад в проведение поисково-аналитической работы и подготовку статьи, прочли и одобрили финальную версию до публикации, Статья поступила в редакцию
Алёна Игоревна -М, Русско-немецкой академии медико-социальных и биотехнологических наук
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop